PPD to Discover Biomarkers for PDL BioPharma
News May 03, 2006
Under the terms of the agreement, PPD's biomarker discovery sciences group will examine specified sample sets utilizing DeepLook™ analysis, its proprietary integrated platform for mass spectrometry-based discovery of biomarkers.
"Identification and implementation of biomarkers can accelerate clinical trials by improving diagnosis, patient selection, and monitoring of disease progression and therapeutic response," said Howard Schulman, vice president of PPD's biomarker discovery sciences.
"We look forward to working with PDL BioPharma to develop biomarkers for its clinical development programs."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019